Advanced search
Publication Cover
Infection and Drug Resistance Volume 14, 2021 - Issue
Submit an article Journal homepage
86
Views
6
CrossRef citations to date
0
Altmetric
Case Series

PMX-DHP Therapy for Dyspnea and Deoxygenation in Severe COVID-19 Pneumonia: A Case Series

Tsukasa Kuwana1 Division of Emergency and Critical Care Medicine, Department of Acute Medicine, Nihon University School of Medicine, Tokyo, JapanORCID Iconhttps://orcid.org/0000-0002-1798-0063
ORCID Icon,
Kosaku Kinoshita1 Division of Emergency and Critical Care Medicine, Department of Acute Medicine, Nihon University School of Medicine, Tokyo, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-9451-9027
ORCID Icon,
Marina Hirabayashi1 Division of Emergency and Critical Care Medicine, Department of Acute Medicine, Nihon University School of Medicine, Tokyo, Japan
,
Shingo Ihara1 Division of Emergency and Critical Care Medicine, Department of Acute Medicine, Nihon University School of Medicine, Tokyo, JapanORCID Iconhttps://orcid.org/0000-0002-2963-415X
ORCID Icon,
Nami Sawada1 Division of Emergency and Critical Care Medicine, Department of Acute Medicine, Nihon University School of Medicine, Tokyo, Japan
,
Tomokazu Mutoh1 Division of Emergency and Critical Care Medicine, Department of Acute Medicine, Nihon University School of Medicine, Tokyo, JapanORCID Iconhttps://orcid.org/0000-0003-3835-8422
ORCID Icon &
Junko Yamaguchi1 Division of Emergency and Critical Care Medicine, Department of Acute Medicine, Nihon University School of Medicine, Tokyo, JapanORCID Iconhttps://orcid.org/0000-0002-6131-0665
ORCID Icon show all
Pages 1305-1310 | Published online: 06 Apr 2021

References

  • Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–1034. doi:10.1016/S0140-6736(20)30628-032192578
  • Antwi-Amoabeng D, Kanji Z, Ford B, Beutler BD, Riddle MS, Siddiqui S. Clinical outcomes in COVID-19 patients treated with tocilizumab: an individual patient data systematic review. J Med Virol. 2020;92(11):2516–2522. doi:10.1002/jmv.2603832436994
  • Bhaskar S, Sinha A, Banach M, et al. Cytokine storm in COVID-19-immunopathological mechanisms, clinical considerations, and therapeutic approaches: the REPROGRAM Consortium position paper. Front Immunol. 2020;11:1648. doi:10.3389/fimmu.2020.0164832754159
  • Shimizu T, Miyake T, Kitamura N, Tani M, Endo Y. Endotoxin adsorption: direct hemoperfusion with the polymyxin B-immobilized fiber column (PMX). Transfus Apher Sci. 2017;56(5):682–688. doi:10.1016/j.transci.2017.08.01528923774
  • Ichiyasu H, Horio Y, Masunaga A, et al. Efficacy of direct hemoperfusion using polymyxin B-immobilized fiber column (PMX-DHP) in rapidly progressive interstitial pneumonias: results of a historical control study and a review of previous studies. Ther Adv Respir Dis. 2017;11(7):261–275. doi:10.1177/175346581770895028554260
  • Enomoto N, Mikamo M, Oyama Y, et al. Treatment of acute exacerbation of idiopathic pulmonary fibrosis with direct hemoperfusion using a polymyxin B-immobilized fiber column improves survival. BMC Pulm Med. 2015;15(1):15. doi:10.1186/s12890-015-0004-425887940
  • Altmayer S, Zanon M, Pacini GS, et al. Comparison of the computed tomography findings in COVID-19 and other viral pneumonia in immunocompetent adults: a systematic review and meta-analysis. Eur Radiol. 2020:1–12.
  • Takeda S, Munakata R, Abe S, et al. Hypercytokinemia with 2009 pandemic H1N1 (pH1N1) influenza successfully treated with polymyxin B-immobilized fiber column hemoperfusion. Intensive Care Med. 2010;36(5):906–907. doi:10.1007/s00134-010-1830-820224904
  • Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020;117(20):10970–10975. doi:10.1073/pnas.200561511732350134
  • Toniati P, Piva S, Cattalini M, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020;19(7):102568. doi:10.1016/j.autrev.2020.10256832376398
  • Furlow B. COVACTA trial raises questions about tocilizumab’s benefit in COVID-19. Lancet Rheumatol. 2020;2(10):e592. doi:10.1016/S2665-9913(20)30313-132929415
  • Kulanthaivel S, Kaliberdenko VB, Balasundaram K, Shterenshis MV, Scarpellini E, Abenavoli L. Tocilizumab in Sars-cov-2 patients with the syndrome of cytokine storm: a narrative review. Rev Recent Clin Trials. 2020;15. doi:10.2174/1574887115666200917110954
  • Abe S, Hayashi H, Seo Y, et al. Reduction in serum high mobility group box-1 level by polymyxin B-immobilized fiber column in patients with idiopathic pulmonary fibrosis with acute exacerbation. Blood Purif. 2011;32(4):310–316. doi:10.1159/00033032521893977
  • Oishi K, Mimura-Kimura Y, Miyasho T, et al. Association between cytokine removal by polymyxin B hemoperfusion and improved pulmonary oxygenation in patients with acute exacerbation of idiopathic pulmonary fibrosis. Cytokine. 2013;61(1):84–89. doi:10.1016/j.cyto.2012.08.03223021430
  • Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol. 2020;92(7):814–818. doi:10.1002/jmv.2580132253759
  • Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020;383(24):2333–2344. doi:10.1056/NEJMoa202883633085857
  • Chen X, Zhao B, Qu Y, et al. Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. Clin Infect Dis. 2020;71(8):1937–1942. doi:10.1093/cid/ciaa44932301997
  • Lin A, He Z-B, Zhang S, Zhang J-G, Zhang X, Yan W-H. Early risk factors for the duration of SARS-CoV-2 viral positivity in COVID-19 patients. Clin Infect Dis. 2020;71(16):2061–2065. doi:10.1093/cid/ciaa49032337591
  • Ramiro S, Mostard RLM, Magro-Checa C, et al. Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study. Ann Rheum Dis. 2020;79(9):1143–1151. doi:10.1136/annrheumdis-2020-21847932719045

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.